Search research articles
Contact Us
Filters
Showing results (111-120 of 432) with videos related to
Page
of 44
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
June 17, 2022
Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes
Valeria Santini, Aristoteles Giagounidis, Christopher G Pelligra, et al.
Cancer
|
October 15, 2010
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes
Mikkael A Sekeres, Hagop Kantarjian, Pierre Fenaux, et al.
Journal of Occupational and Environmental Medicine
|
January 31, 2008
Occupation and lymphoid malignancies: results from a French case-control study
Laurent Orsi, Xavier Troussard, Alain Monnereau, et al.
Blood Cancer Journal
|
November 16, 2018
Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis
Sihem Tarfi, Véronique Harrivel, Florent Dumezy, et al.
Ejhaem
|
August 21, 2023
Next-generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial
Pedro Marques Ramos, Jeea Choi, Catarina D Campbell, et al.
Leukemia Research Reports
|
December 28, 2013
Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study
Benoit de Renzis, Veronique Mansat-De Mas, Eric Wattel, et al.
Blood
|
March 14, 2007
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia
Jean-Luc Harousseau, Jeffrey E Lancet, Josy Reiffers, et al.
Leukemia & Lymphoma
|
January 12, 2018
Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial
Antonio Almeida, Pierre Fenaux, Guillermo Garcia-Manero, et al.
Biochemical Pharmacology
|
June 14, 2011
Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action
Elodie Lainey, Sylvain Thépot, Cyrielle Bouteloup, et al.
Health and Quality of Life Outcomes
|
September 10, 2009
Valuation of transfusion-free living in MDS: results of health utility interviews with patients
Agota Szende, Caroline Schaefer, Thomas F Goss, et al.
Page
of 44
Search research articles
Search
Showing results (111-120 of 432) with videos related to
Sort By:
Page
of 44
Clinical Lymphoma, Myeloma & Leukemia
|
June 17, 2022
Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes
Valeria Santini, Aristoteles Giagounidis, Christopher G Pelligra, et al.
Cancer
|
October 15, 2010
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes
Mikkael A Sekeres, Hagop Kantarjian, Pierre Fenaux, et al.
Journal of Occupational and Environmental Medicine
|
January 31, 2008
Occupation and lymphoid malignancies: results from a French case-control study
Laurent Orsi, Xavier Troussard, Alain Monnereau, et al.
Blood Cancer Journal
|
November 16, 2018
Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis
Sihem Tarfi, Véronique Harrivel, Florent Dumezy, et al.
Ejhaem
|
August 21, 2023
Next-generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial
Pedro Marques Ramos, Jeea Choi, Catarina D Campbell, et al.
Leukemia Research Reports
|
December 28, 2013
Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study
Benoit de Renzis, Veronique Mansat-De Mas, Eric Wattel, et al.
Blood
|
March 14, 2007
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia
Jean-Luc Harousseau, Jeffrey E Lancet, Josy Reiffers, et al.
Leukemia & Lymphoma
|
January 12, 2018
Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial
Antonio Almeida, Pierre Fenaux, Guillermo Garcia-Manero, et al.
Biochemical Pharmacology
|
June 14, 2011
Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action
Elodie Lainey, Sylvain Thépot, Cyrielle Bouteloup, et al.
Health and Quality of Life Outcomes
|
September 10, 2009
Valuation of transfusion-free living in MDS: results of health utility interviews with patients
Agota Szende, Caroline Schaefer, Thomas F Goss, et al.
Page
of 44